Pages that link to "Q44001919"
Jump to navigation
Jump to search
The following pages link to Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy (Q44001919):
Displaying 10 items.
- Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest (Q33567522) (← links)
- Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma (Q34991299) (← links)
- Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin (Q37189149) (← links)
- Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis (Q43077121) (← links)
- Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression (Q46732431) (← links)
- Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience (Q47851380) (← links)
- Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? (Q50608843) (← links)
- Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute (Q51021522) (← links)
- Pirarubicin reduces USP22 expression by inhibiting CREB-1 phosphorylation in HeLa cells (Q64111317) (← links)
- Biology and therapy of malignant solid tumors in childhood (Q81086315) (← links)